Profitability Metrics

Gross Margin
100.00%
Operating Margin
43.44%
Net Margin
49.61%

Efficiency Metrics

Revenue per Expense Ratio
1.77
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
0.2300000000

Balance Sheet Analysis

Current Ratio
0.81
Cash Ratio
0.35
Working Capital
$-1.14M
Debt to Equity
0.02
Debt to Assets
1.66%
Equity Ratio
68.85%

Cash Flow Analysis

Operating Cash Flow Ratio
52.19%
Free Cash Flow Ratio
52.19%
CapEx to Revenue
0.00%
Dividends Paid
$3.98M
Stock Buybacks
$475.00K
Total Shareholder Returns
$4.45M
Cash Position Change
-956,085,600.0%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased R&D investment by 100.00%

Detailed Growth Metrics

Core Performance

Revenue
140.67%
Net Income
118.72%
EPS
118.70%
Operating Income
116.40%

Operational Efficiency

R&D Expenses
100.00%
SG&A Expenses
420.24%
Operating Cash Flow
-2.07%
Free Cash Flow
-2.07%

Balance Sheet Health

Assets
1.58%
Debt
46.34%
Book Value per Share
-1.67%
Inventory
0.00%

Shareholder Returns

Dividends per Share
-0.77%
Shares Outstanding
0.71%

Long Term Trends

3Y Revenue/Share
21.79%
5Y Revenue/Share
249.39%
3Y Dividend/Share
-1.61%
5Y Dividend/Share
-30.41%